A
Alexandra Traverse-Glehen
Researcher at French Institute of Health and Medical Research
Publications - 13
Citations - 878
Alexandra Traverse-Glehen is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Lymphoma & Gray zone lymphoma. The author has an hindex of 9, co-authored 13 publications receiving 693 citations. Previous affiliations of Alexandra Traverse-Glehen include University of Lyon & Claude Bernard University Lyon 1.
Papers
More filters
Journal ArticleDOI
Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria
Estella Matutes,D Oscier,Carlos Montalbán,Françoise Berger,Evelyne Callet-Bauchu,Ahmet Dogan,Pascale Felman,Vito Franco,Emilio Iannitto,Manuela Mollejo,Theodora Papadaki,Ellen D. Remstein,Antonio Salar,Francesc Solé,Kostas Stamatopoulos,Catherine Thieblemont,Alexandra Traverse-Glehen,Andrew Wotherspoon,B. Coiffier,M A Piris +19 more
TL;DR: These guidelines are intended to contribute to the standardization of the diagnosis and treatment of patients with splenic marginal zone lymphoma, and should facilitate the future development of clinical trials that could define more precisely predictive markers for histological progression or lack of response, and evaluate new drugs or treatments.
Journal ArticleDOI
Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes
Camille Laurent,Audrey Delas,P. Gaulard,Corinne Haioun,Anne Moreau,Luc Xerri,Alexandra Traverse-Glehen,Thérèse Rousset,Isabelle Quintin-Roue,Tony Petrella,Jean-François Emile,Nadia Amara,Philippe Rochaix,M.P. Chenard-Neu,A.M. Tasei,E. Menet,H. Chomarat,V. Costes,L. Andrac-Meyer,Jean-François Michiels,Catherine Chassagne-Clément,L. de Leval,Pierre Brousset,Georges Delsol,Laurence Lamant +24 more
TL;DR: In situ ALK-negative anaplastic large cell lymphoma associated with breast implant have an indolent clinical course and generally remain free of disease after implant removal, however, infiltrative i-ALCLs could have a more aggressive clinical course that might require additional therapy to implant removal.
Journal ArticleDOI
Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection.
Alexandra Traverse-Glehen,Frederic Davi,Ben Simon E,Evelyne Callet-Bauchu,Pascale Felman,L. Baseggio,Sophie Gazzo,Catherine Thieblemont,Carole Charlot,B. Coiffier,Françoise Berger,Gilles Salles +11 more
TL;DR: The pattern of somatic mutation and the VH gene segment usage appear to differ between SMZL and NMZL, suggesting that these are distinct pathological entities, and a biased usage of certain sequences suggests that tumor cells inSMZL may be subjected to antigen selection.
Journal ArticleDOI
A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases.
Alexandra Traverse-Glehen,Pascale Felman,Evelyne Callet-Bauchu,Sophie Gazzo,L. Baseggio,P. A. Bryon,Catherine Thieblemont,Bertrand Coiffier,Gilles Salles,Françoise Berger +9 more
TL;DR: Clinical findings of 21 cases of primary nodal marginal zone B‐cell lymphoma (NMZL) are reported to report the clinicopathological findings.
Journal ArticleDOI
Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.
Fabrice Jardin,Anais Pujals,Laura Pelletier,Elodie Bohers,Vincent Camus,Sylvain Mareschal,Sydney Dubois,Brigitte Sola,Marlene Ochmann,François Lemonnier,Pierre-Julien Viailly,Philippe Bertrand,Catherine Maingonnat,Alexandra Traverse-Glehen,Philippe Gaulard,Diane Damotte,Richard Delarue,Corinne Haioun,Christian Argueta,Yosef Landesman,Gilles Salles,Jean-Philippe Jais,Martin Figeac,Christiane Copie-Bergman,Thierry Jo Molina,Jean Michel Picquenot,Marie Cornic,Thierry Fest,Noel Milpied,Emilie Lemasle,Aspasia Stamatoullas,Peter Moeller,Martin J. S. Dyer,Christer Sundström,Christian Bastard,Hervé Tilly,Karen Leroy +36 more
TL;DR: The XPO1 E571K mutation represents a genetic hallmark of the PMBL subtype and serves as a new relevant PMBL biomarker.